Seelos Therapeutics (Seelos Therapeutics) EPS (Diluted) : $-82.64 (TTM As of Mar. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Seelos Therapeutics EPS (Diluted)?

Seelos Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-1.60. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-82.64.

Seelos Therapeutics's EPS (Basic) for the three months ended in Mar. 2024 was $-1.60. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-34.64.

Seelos Therapeutics's EPS without NRI for the three months ended in Mar. 2024 was $-3.82. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-86.47.

During the past 3 years, the average EPS without NRIGrowth Rate was 12.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 44.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 40.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Seelos Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 84.00% per year. The lowest was -209.60% per year. And the median was 14.15% per year.

Seelos Therapeutics EPS (Diluted) Historical Data

The historical data trend for Seelos Therapeutics's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seelos Therapeutics EPS (Diluted) Chart

Seelos Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

Get a 7-Day Free Trial

-604.80

-103.20

-175.20

-165.92

-61.84

Seelos Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Diluted)	Get a 7-Day Free Trial															-28.64	-52.80	-28.80	0.56	-1.60

Competitive Comparison of Seelos Therapeutics's EPS (Diluted)

For the Biotechnology subindustry, Seelos Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Seelos Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seelos Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Seelos Therapeutics's PE Ratio falls into.

Seelos Therapeutics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Seelos Therapeutics's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-37.882	-	0)	/	0.613
	=	-61.80

Seelos Therapeutics's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-2.664	-	0)	/	1.626
	=	-1.64

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-82.64

Seelos Therapeutics (NAS:SEEL) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Seelos Therapeutics EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Seelos Therapeutics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Seelos Therapeutics (Seelos Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seelos Therapeutics Inc (NAS:SEEL) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 Park Avenue, 2nd Floor, New York, NY, USA, 10022

Website

https://www.seelostherapeutics.com

Seelos Therapeutics Inc is a clinical-stage biotechnology company. The company is focused on developing products that address unmet needs in Central Nervous System (CNS) disorders and other rare disorders.

Executives

Raj Mehra	director, officer: See Remarks	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Michael Joseph Golembiewski	officer: Chief Financial Officer	7 TURTLE CT, FLEMINGTON NJ 08822
Daniel J. O'connor	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Margaret Dalesandro	director	ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Judith Dunn	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Brian Lian	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Robin L Smith	director	C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
Neil Morton	officer: SVP, Chief Business Officer	C/O APRICUS BIOSCIENCES, INC., 11975 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Richard W Pascoe	director, officer: CEO & Secretary	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Alexander J Denner	10 percent owner	C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Management Lp	10 percent owner	660 STEAMBOAT ROAD, GREENWICH CT 06830
Sarissa Capital Domestic Fund Lp	10 percent owner	660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830